Glycolysis has ten enzymatic steps, and three of them are effectively one-way reactions in living cells: the hexokinase reaction (step 1), the phosphofructokinase-1 reaction (step 3), and the pyruvate kinase reaction (step 10). These three steps release so much energy that they cannot run in reverse under normal cellular conditions, which is why the cell uses entirely different enzymes to reverse them when it needs to build glucose back up. Their irreversibility also makes them the pathway’s natural control points, where the cell decides how fast to burn glucose.
Step 1: Hexokinase Traps Glucose Inside the Cell
The moment glucose enters a cell, hexokinase slaps a phosphate group onto it, converting it to glucose-6-phosphate. This reaction is the rate-limiting first step of glycolysis and costs one molecule of ATP.1PubMed Central. Hexokinase II integrates energy metabolism and cellular protection: Akting on mitochondria and TORCing to autophagy The phosphate group gives glucose a negative charge, which prevents it from slipping back out through the membrane’s glucose transporters. In practical terms, hexokinase is the cell’s commitment to at least capturing the glucose molecule. Once phosphorylated, glucose is stuck inside.
This reaction is irreversible because it releases a significant amount of free energy. Under the conditions inside a typical cell, the forward reaction is so strongly favored that the reverse essentially never happens on its own. To undo it, the cell needs a completely different enzyme, glucose-6-phosphatase, which is found primarily in the liver and kidneys. Most tissues lack that enzyme, which is one reason most cells cannot export glucose back into the bloodstream.
Hexokinase comes in several varieties. Most tissues express forms that are inhibited by their own product: when glucose-6-phosphate builds up, hexokinase slows down. The liver, however, uses a variant called glucokinase that behaves differently. Glucokinase has a much lower affinity for glucose and responds to rising blood sugar in a gradual, sensor-like way rather than switching on all at once.2PubMed. Glucokinase: from allosteric glucose sensing to disease variants This makes the liver a kind of glucose buffer: it ramps up glucose processing proportionally as blood sugar climbs after a meal and backs off when levels drop.
Step 3: Phosphofructokinase-1, the Gatekeeper
If hexokinase is the cell’s way of capturing glucose, phosphofructokinase-1 (PFK-1) is the point of no return. PFK-1 converts fructose-6-phosphate into fructose-1,6-bisphosphate, spending a second ATP in the process. This is widely considered the true committed step of glycolysis: once fructose-1,6-bisphosphate is made, the molecule is locked into the glycolytic pathway.3PubMed Central. Structural basis for allosteric regulation of human phosphofructokinase-1 Glucose-6-phosphate from step 1 still has options; it can be shunted toward glycogen storage or the pentose phosphate pathway. But after PFK-1 acts, the sugar is committed to being broken down for energy. That is why PFK-1 is sometimes called the gatekeeper of glycolysis.4PubMed. Phosphofructokinase in glycolysis: Bridging enzymology and cell biology
Because PFK-1 sits at such a critical junction, the cell layers on more regulatory inputs here than at any other glycolytic step. The enzyme is sensitive to ATP levels, AMP levels, citrate, and a powerful activator called fructose-2,6-bisphosphate. When ATP is abundant, PFK-1 slows down because the cell does not need more energy. When AMP rises (a sign that ATP has been depleted), PFK-1 speeds up. Citrate, an intermediate from the next stage of energy metabolism, also inhibits PFK-1, providing feedback that says “we already have plenty of fuel downstream.”5Journal of Biological Chemistry. Fructose 2,6-Bisphosphate and Glycolytic Oscillations in Skeletal Muscle Extracts
The most potent activator of PFK-1 is fructose-2,6-bisphosphate, a signaling molecule produced by a separate bifunctional enzyme. This bifunctional enzyme can both make and destroy fructose-2,6-bisphosphate depending on hormonal signals. In the liver, when glucagon rises (a sign of low blood sugar), the enzyme shifts toward breaking down fructose-2,6-bisphosphate, which pulls the brake on glycolysis. When insulin is high (a sign of abundant blood sugar), the opposite happens and glycolysis accelerates.6PubMed Central. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis In the heart, a different version of the same enzyme is activated by entirely different signaling pathways, reflecting the heart’s unique energy demands. This layered control makes PFK-1 the single most tightly regulated enzyme in glycolysis.
Step 10: Pyruvate Kinase Delivers the Final Payoff
The last irreversible step is the conversion of phosphoenolpyruvate (PEP) to pyruvate by pyruvate kinase, which produces the second ATP molecule generated directly in glycolysis. The equilibrium of this reaction is overwhelmingly in the forward direction, with an equilibrium constant on the order of a thousand to ten thousand, making it essentially a one-way street.7Structure. Structure of Yeast Pyruvate Kinase Complexed with Substrate, Mn2+, K+, and Fructose-1,6-bisphosphate The pyruvate produced here stands at a metabolic crossroads: it can enter the mitochondria for aerobic energy production, or it can be converted to lactate under low-oxygen conditions.
Pyruvate kinase is also subject to regulation by acetylation, a chemical modification that helps the cell fine-tune how much carbon flows through the end of glycolysis.8PubMed Central. Regulation of glycolysis and gluconeogenesis by acetylation of PKM and PEPCK Like the other irreversible enzymes, pyruvate kinase is activated by upstream intermediates (fructose-1,6-bisphosphate acts as a feed-forward signal) and inhibited when the cell’s energy charge is already high. This creates a coordinated system: the gatekeeper at step 3 and the final checkpoint at step 10 respond to many of the same signals, keeping the whole pathway in sync.
Why These Three and Not the Others
The other seven steps of glycolysis operate near equilibrium, meaning their reactions can run forward or backward depending on which direction the concentrations of reactants and products push them. They are like water flowing down a gentle slope that could reverse if you raised the downstream level. The three irreversible steps, by contrast, are like waterfalls: so much energy is released going forward that you would need an entirely different route to get back up.
This distinction matters because it determines where the cell can exert control. Enzymes operating near equilibrium respond mainly to the concentrations of their substrates and products; you cannot easily speed them up or slow them down independently. But an enzyme catalyzing an irreversible step is already far from equilibrium, so tweaking its activity with activators or inhibitors can directly change how fast the whole pathway runs. That is why essentially all of the pathway’s hormonal and allosteric regulation converges on these three enzymes rather than being spread across all ten steps.
How Gluconeogenesis Gets Around the One-Way Steps
When the body needs to manufacture glucose rather than burn it, it runs a pathway called gluconeogenesis that is essentially glycolysis in reverse. But it cannot literally reverse the three irreversible steps, so it uses bypass enzymes instead. Glucose-6-phosphatase replaces hexokinase, fructose-1,6-bisphosphatase replaces PFK-1, and a two-enzyme sequence involving pyruvate carboxylase and phosphoenolpyruvate carboxykinase (PEPCK) replaces pyruvate kinase.
These bypass enzymes are critical because the cell must never run glycolysis and gluconeogenesis simultaneously at the same steps. If both directions were active at once, the result would be a futile cycle: the cell would burn ATP to make a product and then immediately spend more ATP to unmake it, generating nothing but heat. Cells prevent this by using allosteric regulation to ensure that when the glycolytic enzyme at a given step is active, the gluconeogenic bypass enzyme is suppressed, and vice versa.9PLOS Pathogens. Fitness of Escherichia coli during Urinary Tract Infection Requires Gluconeogenesis and the TCA Cycle The fructose-2,6-bisphosphate system described earlier is a perfect example: the same signaling molecule that activates PFK-1 also inhibits fructose-1,6-bisphosphatase, so the two pathways cannot clash.
In rare situations, partial futile cycling does occur and may even serve a purpose. Some researchers think a small amount of simultaneous forward and reverse flux allows the cell to respond more quickly to sudden changes in energy demand, acting as a kind of metabolic idling. But under normal conditions, cells work hard to keep the irreversible steps running in only one direction at a time.
When the Irreversible Enzymes Go Wrong
Because these three enzymes sit at such crucial control points, genetic defects in any of them can cause disease. The best-known example involves glucokinase, the liver and pancreatic variant of hexokinase. Mutations in the glucokinase gene disrupt the pancreas’s ability to sense blood glucose levels, leading to a form of diabetes known as maturity-onset diabetes of the young, or MODY.10PubMed. Molecular etiologies of MODY and other early-onset forms of diabetes People with MODY-2 (the glucokinase subtype) tend to have mildly elevated blood sugar from birth, because their pancreatic beta cells set the threshold for insulin release too high. The condition is often so mild that it goes undiagnosed for years, and many patients manage it without medication.
Cancer offers a more dramatic illustration. Tumor cells famously consume glucose at a much higher rate than normal cells, even when oxygen is plentiful, a phenomenon known as the Warburg effect. Hexokinase II, in particular, is frequently overexpressed in aggressive tumors.11PubMed Central. Hexokinase II promotes the Warburg effect by phosphorylating alpha subunit of pyruvate dehydrogenase Cancer cells gain several advantages by cranking up this first irreversible step. By attaching hexokinase II directly to the outer membrane of mitochondria, tumor cells give the enzyme privileged access to freshly made ATP for phosphorylating glucose. The resulting glucose-6-phosphate is trapped inside the cell, and much of it gets funneled not just into energy production but into biosynthetic pathways that supply raw materials for rapid cell division.12PubMed Central. Hexokinase-2 bound to mitochondria: cancer’s stygian link to the “Warburg Effect” and a pivotal target for effective therapy Mitochondrial binding of hexokinase II also helps cancer cells resist programmed cell death, making the enzyme a double asset for tumor survival.
Pyruvate kinase is equally interesting in cancer biology. Many tumors express a specific splice variant of pyruvate kinase that is less active than the version found in most adult tissues. This sounds counterintuitive for cells that are supposedly addicted to glucose, but the slower pyruvate kinase allows glycolytic intermediates to pile up and spill into branching biosynthetic pathways rather than racing all the way to pyruvate. The irreversible enzymes of glycolysis are thus not just energy gates but metabolic routing switches, and cancer cells exploit that routing capacity aggressively.
Hexokinases Do More Than Glycolysis
One of the more surprising findings in recent years is that hexokinases have roles that go well beyond sugar metabolism. Researchers have documented hexokinase activity in gene regulation, immune signaling, autophagy, and even serving as a protein kinase, phosphorylating other proteins rather than glucose.13PubMed Central. Moonlighting Proteins: The Case of the Hexokinases In plants, hexokinase acts as a glucose sensor that influences gene expression related to growth and development. In animal immune cells, hexokinase can function as an intracellular receptor that detects bacterial cell-wall components and triggers inflammatory responses.
These “moonlighting” functions are a reminder that the irreversible glycolytic enzymes evolved under multiple selective pressures simultaneously. Their catalytic role in sugar metabolism is what gets them into every biochemistry textbook, but their non-metabolic activities are increasingly recognized as equally consequential. When cancer researchers target hexokinase II, for instance, they need to account for the fact that inhibiting the enzyme might not just slow down glycolysis but could also affect cell-death pathways and immune signaling in unpredictable ways.
Not All Organisms Use the Same Enzymes
The three-irreversible-step framework applies cleanly to the “classical” glycolytic pathway found in animals, plants, fungi, and most bacteria. But archaea, a separate domain of life that thrives in extreme environments, often use modified versions of glycolysis with different enzymes at these control points. Some archaea use ADP-dependent kinases instead of the ATP-dependent hexokinase and phosphofructokinase found in other organisms, and the enzymes that handle later steps can also differ substantially.14PubMed. Unusual pathways and enzymes of central carbohydrate metabolism in Archaea
These variations suggest that while the general logic of glycolysis (invest a little energy up front, break a six-carbon sugar into two three-carbon pieces, harvest energy on the back end) is ancient and nearly universal, the specific molecular hardware is more flexible than textbooks imply. The irreversible steps still exist in archaeal glycolysis, but they are catalyzed by enzyme families that share little sequence similarity with their counterparts in humans or bacteria. This matters for researchers hunting for antibiotics or antifungal drugs: enzymes that are essential in a pathogen but structurally different from the human version make attractive drug targets, and the irreversible glycolytic steps are a natural place to look.
Why Textbooks Call Them “Irreversible” (and What That Really Means)
Strictly speaking, no chemical reaction is truly irreversible in the absolute sense. Given extreme enough conditions, any reaction can be pushed backward. When biochemists call these three glycolytic steps irreversible, they mean that under the actual conditions inside a living cell, with real concentrations of substrates, products, ions, and cofactors, the reverse reaction proceeds at a negligible rate. The free energy difference is so large that the probability of reversal is vanishingly small.
This is a useful distinction to keep in mind. In a test tube, with purified enzyme and carefully manipulated concentrations, you could force even the hexokinase reaction to run backward. Cells never encounter those conditions. The term “irreversible” in glycolysis is a statement about physiology, not about chemistry in the abstract. It also explains why the cell does not waste regulatory machinery on the other seven steps: those near-equilibrium reactions will sort themselves out based on concentration gradients alone, while the three irreversible steps need active oversight to keep glycolysis running at the right pace for the cell’s current needs.